Sagent Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SGNT)

$21.76 0.03 (0.14 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$21.73
Today's Range$21.74 - $21.76
52-Week Range$10.55 - $21.88
Volume260,400 shs
Average Volume607,514 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Sector: Pharmaceuticals - NEC
  • Symbol: NASDAQ:SGNT
  • CUSIP: 78669210
  • Web: www.sagentpharma.com
Profitability:
  • Trailing EPS: ($0.77)
  • Net Margins: -0.72%
  • Return on Equity: -0.81%
  • Return on Assets: -0.59%
Misc:
  • Outstanding Shares: 33,090,000
 
Frequently Asked Questions for Sagent Pharmaceuticals (NASDAQ:SGNT)

What is Sagent Pharmaceuticals' stock symbol?

Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."

How were Sagent Pharmaceuticals' earnings last quarter?

Sagent Pharmaceuticals Inc (NASDAQ:SGNT) released its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.01 by $0.16. The business earned $67.30 million during the quarter, compared to analyst estimates of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. The firm's revenue for the quarter was down 17.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.04 earnings per share. View Sagent Pharmaceuticals' Earnings History.

Who are some of Sagent Pharmaceuticals' key competitors?

How do I buy Sagent Pharmaceuticals stock?

Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sagent Pharmaceuticals' stock price today?

One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.76.

How can I contact Sagent Pharmaceuticals?

Sagent Pharmaceuticals' mailing address is 1901 N Roselle Rd Ste 700, SCHAUMBURG, IL 60195-3194, United States. The company can be reached via phone at +1-847-9081604.


MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  352
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A
Consensus Price Target History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Price Target History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2016Deutsche Bank AGDowngradeBuy -> HoldN/AView Rating Details
7/12/2016Raymond James Financial, Inc.DowngradeBuy -> Market PerformN/AView Rating Details
7/11/2016Royal Bank Of CanadaDowngradeOutperform -> HoldN/AView Rating Details
7/11/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $21.75N/AView Rating Details
6/17/2016Jefferies Group LLCReiterated RatingHold$13.00 -> $15.00N/AView Rating Details
6/1/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
5/9/2016Bank of America CorporationReiterated RatingHold$13.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Earnings by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Earnings History by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details
11/5/2013($0.03)$0.10ViewN/AView Earnings Details
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sagent Pharmaceuticals (NASDAQ SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sagent Pharmaceuticals (NASDAQ:SGNT)
Latest Headlines for Sagent Pharmaceuticals (NASDAQ SGNT)
Source:
DateHeadline
Corcept Therapeutics (CORT) and Sagent Pharmaceuticals (SGNT) Critical AnalysisCorcept Therapeutics (CORT) and Sagent Pharmaceuticals (SGNT) Critical Analysis
www.americanbankingnews.com - November 14 at 3:39 PM
Head-To-Head Survey: Dr. Reddys Laboratories (RDY) & Sagent Pharmaceuticals (SGNT)Head-To-Head Survey: Dr. Reddy's Laboratories (RDY) & Sagent Pharmaceuticals (SGNT)
www.americanbankingnews.com - November 11 at 11:26 PM
Sagent Pharmaceuticals (SGNT) vs. Astrazeneca PLC (AZN) Financial ReviewSagent Pharmaceuticals (SGNT) vs. Astrazeneca PLC (AZN) Financial Review
www.americanbankingnews.com - October 22 at 10:18 PM
Financial Review: Innocoll Holdings PLC (INNL) versus Sagent Pharmaceuticals (SGNT)Financial Review: Innocoll Holdings PLC (INNL) versus Sagent Pharmaceuticals (SGNT)
www.americanbankingnews.com - October 21 at 8:15 AM
Reviewing Sagent Pharmaceuticals (SGNT) & Its PeersReviewing Sagent Pharmaceuticals (SGNT) & Its Peers
www.americanbankingnews.com - October 20 at 12:22 PM
Analyzing Sagent Pharmaceuticals (SGNT) and Its CompetitorsAnalyzing Sagent Pharmaceuticals (SGNT) and Its Competitors
www.americanbankingnews.com - October 18 at 9:42 AM
Financial Analysis: Sagent Pharmaceuticals (SGNT) vs. Cellectar Biosciences (CLRB)Financial Analysis: Sagent Pharmaceuticals (SGNT) vs. Cellectar Biosciences (CLRB)
www.americanbankingnews.com - October 15 at 10:38 AM
Form 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman AnthonyForm 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony
www.streetinsider.com - September 1 at 7:13 PM
Nichi-Iko Pharmaceutical Co., Ltd.Nichi-Iko Pharmaceutical Co., Ltd.
www.thestreet.com - August 30 at 10:37 AM
Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.
au.finance.yahoo.com - August 29 at 7:14 PM
SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of DelistSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist
biz.yahoo.com - August 29 at 7:14 PM
Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc.Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc.
www.streetinsider.com - August 9 at 7:41 PM
Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.
au.finance.yahoo.com - August 9 at 10:37 AM
SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportSAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - August 5 at 7:38 PM

Social Media

Financials

Chart

Sagent Pharmaceuticals (NASDAQ SGNT) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.